Vertex, CRISPR finish rolling submission of application for sickle cell candidate
Bill Oxford         

Vertex Pharmaceuticals (NASDAQ:VRTX) and CRISPR Therapeutics (CRSP) have completed a rolling submission of a Biologics License Application to the US FDA for exagamglogene autotemcel (exa-cel) for sickle cell disease and transfusion-dependent beta thalassemia.
The companies are requesting Priority Review.
The application is supported by two ongoing phase 3 studies, and an additional long-term study.
The FDA has granted exa-cel Regenerative Medicine Advanced Therapy, Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA for both indications.
Read why Seeking Alpha contributor SL Investments just reiterated a buy rating for CRISPR (CRSP).